Shapiro WR, Young DF, Mehta BM (1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293(4):161–166

Article  CAS  PubMed  Google Scholar 

Kieffer SA, Stadlan EM, D’Angio GJ (1969) Anatomic studies of the distribution and effects of intrathecal radioactive gold. Acta Radiol Ther Phys Biol 8(1–2):27–37

Article  CAS  PubMed  Google Scholar 

Posner JB (1973) Reservoirs for intraventricular chemotherapy. N Engl J Med 288(4):212

Article  CAS  PubMed  Google Scholar 

Perrin RG, Lishner M, Guha A et al (1990) Experience with Ommaya reservoir in 120 consecutive patients with meningeal malignancy. Can J Neurol Sci 17:190–192

Article  CAS  PubMed  Google Scholar 

Peyrl A, Chocholous M, Azizi AA et al (2014) Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. J Neurooncol 120(1):139–145

Article  CAS  PubMed  Google Scholar 

Szvalb AD, Raad II, Weinberg JS et al (2014) Ommaya reservoir-related infections: clinical manifestations and treatment outcomes. J Infect 68(3):216–224

Article  PubMed  Google Scholar 

Mead PA, Safdieh JE, Nizza P et al (2014) Ommaya reservoir infections: a 16-year retrospective analysis. J Infect 68(3):225–230

Article  PubMed  Google Scholar 

Sandberg DI, Bilsky MH, Souweidane MM et al (2000) Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 47(1):49–55

CAS  PubMed  Google Scholar 

Ratcheson RA, Ommaya AK (1968) Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N Engl J Med 279(19):1025–1031

Article  CAS  PubMed  Google Scholar 

Bleyer WA, Poplack DG, Simon RM (1978) Concentration x time methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51(5):835–842

Article  CAS  PubMed  Google Scholar 

Bleyer WA, Poplack DG (1979) Intraventricular versus intra lumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 6(3):207–213

Article  CAS  PubMed  Google Scholar 

Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87(5):694–699

Article  CAS  PubMed  Google Scholar 

Green DM, West CR, Brecher ML et al (1982) The use of subcutaneous cerebrospinal fluid reservoirs for the prevention and treatment of meningeal relapse of acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 4(2):147–154

CAS  PubMed  Google Scholar 

Haghbin M, Galicich JH (1979) Use of the Ommaya reservoir in the prevention and treatment of CNS leukemia. Am J Pediatr Hematol Oncol 1(2):111–117

CAS  PubMed  Google Scholar 

Moser AM, Adamson PC, Gillespie AJ et al (1999) Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 85(2):511–516

Article  CAS  PubMed  Google Scholar 

Spiers AS, Booth AE, Firth JL (1978) Subcutaneous cerebrospinal fluid reservoirs in patients with acute leukaemia. Scan J Haematol 20(4):289–296

Article  CAS  Google Scholar 

Steinherz P, Jereb B, Galicich J (1985) Therapy of CNS leukemia with intraventricular chemotherapy and low-dose neuraxis radiotherapy. J Clin Oncol 3(9):1217–1226

Article  CAS  PubMed  Google Scholar 

Strother DR, Glynn-Barnhart A, Kovnar E et al (1989) Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing. J Clin Oncol 7(11):1741–1747

Article  CAS  PubMed  Google Scholar 

Wilson R, Osborne C, Halsey C (2018) The use of Ommaya reservoirs to deliver central nervous system directed chemotherapy in childhood acute lymphoblastic leukaemia. Paediatr Drugs 20(4):293–301

Article  PubMed  Google Scholar 

Bleyer AW (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61(8):1419–1425

CAS  PubMed  Google Scholar 

Ettinger LJ, Chervinsky DS, Freeman AI et al (1982) Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and Non-hodgkin’s lymphoma. Cancer 50(90):1676–1682

Article  CAS  PubMed  Google Scholar 

Pauley JL, Panetta JC, Crews KR et al (2013) Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72(2):369–378

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bleyer WA, Drake JC, Chabner BA (1973) Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 289(15):770–773

Article  CAS  PubMed  Google Scholar 

Hryniuk WM, Bertino JR (1969) Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest 48(11):2140–2155

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keefe DA, Capizzi RL, Rudnick SA (1982) Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42(5):1641–1645

CAS  PubMed  Google Scholar 

Mauer AM (1975) Cell kinetics and practical consequences for therapy of acute leukemia. N Engl J Med 293(8):389–393

Article  Google Scholar 

Bhojwani D, Sabin ND, Pei D et al (2014) Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32(9):949–959

Article  CAS  PubMed  PubMed Central  Google Scholar